Author:
Billah M. Motasim,Cooper Nicola,Minnicozzi Michael,Warneck Julie,Wang Peng,Hey John A.,Kreutner William,Rizzo Charles A.,Smith Sidney R.,Young Simon,Chapman Richard W.,Dyke Hazel,Shih Nang-Yang,Piwinski John J.,Cuss Francis M.,Montana John,Ganguly Ashit K.,Egan Robert W.
Publisher
American Society for Pharmacology & Experimental Therapeutics (ASPET)
Subject
Pharmacology,Molecular Medicine
Reference34 articles.
1. SB207499 (Ariflo), a potent and selective second generation phosphodiesterase 4 inhibitor: in vitro antiinflammatory actions.;Barnette;J Pharmacol Exp Ther,1998
2. New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease
3. Asthma: where beyond steroids?
4. In vivo efficacy in airway disease models of Roflumilast, a novel orally active PDE4 inhibitor.;Bundschuh;J Pharmacol Exp Ther,2001
5. Ariflo improves pulmonary function in patients with asthma: results of a study in patients taking inhaled corticosteroids.;Compton;Am J Respir Crit Care Med,1999
Cited by
40 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献